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Abstract
Acetylsalicylic acid is a frequently used medication worldwide. It is not used in pediatrics due its association with
Reye syndrome. However, in case of pediatric intoxication, children are more fragile to salicylate poisoning because
of their reduced ability of buffer the acid stress. Intoxication leads to a decoupling of oxidative phosphorylation and
subsequently to a loss in mitochondrial function. Symptoms of poisoning are diverse; eventually they can lead to
the death of the patient. Governmental websites of various EU countries were searched for legal information on
acetylsalicylic acid availability in pharmacies and non-pharmacy stores. Various EU countries permit prescription-free
sales of acetylsalicylic acid in pharmacies and non-pharmacy stores. In Sweden acetylsalicylic acid 500 mg may be sold
in a maximum package size of 20 tablets or effervescent tablets in a non-pharmacy. In the UK a maximum of 16 tablets
of acetylsalicylic acid 325 mg is allowed to sell in non-pharmacies. In Ireland acetylsalicylic acid is classified as S2
medication. Subsequently, acetylsalicylic acid is allowed to be sold prescription-free in pharmacies and non-pharmacy
stores. In the Netherlands acetylsalicylic acid may only be sold in drug stores or pharmacies. A maximum of 24 tablets
of 500 mg is allowed to purchase in a drug store. Several countries in the European Union are permitted to offer
acetylsalicylic acid prescription-free in pharmacies and non-pharmacy stores without legal guidance on the storage
position within the store. Further research is needed to investigate whether acetylsalicylic acid is located directly
accessible to young children within the stores in EU countries which permit prescription-free sales of acetylsalicylic acid.
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Background
Recently we published a narrative review about paraceta-
mol as a toxic substance for children [1]. Accordingly,
the present review will focus on another important anal-
gesic as a potential pediatric health hazard: acetylsalicylic
acid. It is one of the most wildly used analgesic and anti-
platelet medication throughout the world. It is com-
monly known as aspirin, which is the product name
introduced by the pharmaceutical company Bayer AG.
Figure 1 shows the chemical structure of acetylsalicylic
acid. In order to avoid Reye syndrome, it is not com-
monly used in pediatric treatment any more. Nonethe-
less, acute poisoning in children can occur by accidental
ingestion of adult medication [2, 3]. This narrative
review summarizes the effects of acetylsalicylic acid in-
toxication, especially in children. Additionally, it outlines
the current legal requirements on acetylsalicylic acid
sales in various countries ofthe European Union. The
goal was to establish whether the pharmaceutical might
be accessible to young children within pharmacies and
non-pharmacy stores.
Acetylsalicylic acid toxicity
The acetylsalicylic acid metabolite salicylate affects most
organ systems. It decouples oxidative phosphorylations
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like the Krebs cycle and amino acid synthesis. On a mo-
lecular level it increases oxidative stress and subse-
quently results in a loss of mitochondrial potential; the
consequence is a damaged mitochondrial respiratory
function. Initially, acetylsalicylic acid poisoning leads to
pure respiratory alkalosis due to activation of the re-
spiratory center in the medulla oblongata. Thereafter,
acetylsalicylic acid poisoning causes anaerobic oxidation
which results in anion gap metabolic acidosis; the un-
detected anions include salicylates and lactate [4–6].
The typical triad of acetylsalicylic acid intoxication con-
sists of hyperventilation, tinnitus and gastrointestinal
symptoms such as vomiting and nausea. Other early
symptoms include hematemesis, deafness, lethargy and
confusion. Pulmonary edema, hemorrhages and hyper-
glycemia have also been observed. Serious poisoning can
additionally lead to hepatotoxicity. After severe intoxica-
tion, central nervous system (CNS) changes like agita-
tion and confusion might occur with a risk of cerebral
edema; these symptoms can lead to coma. Acetylsalicylic
acid intoxication can eventually result in the death of
the patient [2, 7, 8]. One study reported a case of a child
with detected high acetylsalicylic acid blood levels suffer-
ing from acute myocarditis. These findings suggest a
causal relationship between myocarditis and acetylsali-
cylic acid overdose [9].
Acetylsalicylic acid intoxication in children
The acetylsalicylic acid metabolite salicylate has been
listed amongst the nine pediatric poisons which lead to
death in children at low doses [10]. Young children are
more fragile to salicylate poisoning because they cannot
compensate acid stress as effectively as adults; CNS
changes like agitation and restlessness are especially
widespread in children [2]. The acute toxic acetylsalicylic
acid dosage is considered to be more than 150 mg/kg
body weight [8]. Salicylate intoxication is probably
under-represented in poison center data because the
symptoms are unspecific and intoxication is often not
diagnosed as such [7]. A US study showed that uninten-
tional acetylsalicylic acid poisoning in children was a
common problem around 1970. At that time it was the
most frequent medicine leading to accidental poisoning
in children. Improving child-proof pharmaceutical con-
tainers lead to a decrease of acetylsalicylic acid intoxica-
tion in children under 5 years [11]. Statistical data on
acetylsalicylic acid intoxication in children is unfortu-
nately limited. This particular intoxication is often not
registered specifically in central statistical databases.
Governmental agencies in various countries published
reports on child injury. Data is usually based on hospital
statistics and death cause statistics; these statistics in-
form about diverse child injury mechanisms. Poisoning
is generally registered as one of them, but the reports
do not provide information about particular drugs. Ac-
cordingly, they do not present statistical information
about drug poisonings with acetylsalicylic acid in chil-
dren [12–14]. In all four countries which were included
in this study poison control centers are installed; they
generally function as advisor for telephone enquiries
made by medical professionals or the general public.
Poison control centers usually document information
about calls, for example the reason for the phone call
or whether the patient is a child. However, in these re-
ports poisoning incidences are often registered by sub-
stance group, for example analgesics, but do not show
data about acetylsalicylic acid specifically [15–18].
Treatment of acute acetylsalicylic acid intoxication
An antidote for acetylsalicylic acid intoxication is not
known. Active charcoal should be administered immedi-
ately after ingestion to reduce the quantity of absorbed
substance. Emesis should not be forced in children suf-
fering from acute acetylsalicylic acid poisoning; whole
bowel irrigation or gastric lavage is also not recom-
mended any more [7, 8]. Serum acetylsalicylic acid levels
should be identified and blood gas analysis should be
performed repeatedly. Severity of intoxication does often
not correlate with the absolute serum level; therefore
blood analysis should be repeated and used to monitor
serum level changes. A nomogram was developed in
1960 by A.K. Done to establish a treatment threshold on
basis of serum acetylsalicylic acid levels. However, due to
serious limitations of the nomogram is not generally
used [7]. Further conservative treatments of acetylsali-
cylic acid poisoning include rehydration and correction
of electrolyte aberrations. Urinary alkalinization is im-
portant in order to accelerate the ionization of the drug
and therefore force renal elimination [19]. Hemodialysis
is a treatment which is commonly used in patients after
acetylsalicylic acid poisoning, even though no clear re-
gime exists concerning duration and best method. If a
Fig. 1 Chemical structure of aspirin, modified after [36]
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decision on hemodialysis is made, alkalinization of urine
should nevertheless be promptly administered [20, 21].
Mechanical ventilation should not be applied to patients
with acetylsalicylic acid intoxication as it results in abol-
ishment of respiratory alkalosis. Mechanical ventilation
aggravates the neurological toxic effects because more
salicylate can pass to the CNS [22]. It is suggested that
balanced glutathione homeostasis in hepatic cells re-
duces the cytotoxic effects of acetylsalicylic acid [6].
Pharmaceutical legislation in European Union countries
European Union countries receive legislation from two
different legislative authorities. On the one hand, na-
tional governments enact laws which apply to every dis-
tinct country individually. On the other hand, laws in
EU countries can be enacted by the EU; the European
Commission (EC), the European Parliament (EP) and
the European Council form the EU legislative body. The
EC proposes legislation which is discussed and eventu-
ally enacted by the EP and the European Council. Two
different types of legislation are performed by the EU:
regulations and directives. An EU regulation is instantly
enforced as law in all EU member countries at the same
time; it excels national law. EU directives are guidelines
with a defined goal and time period in which it has to be
incorporated into national law. Legislation processes
on EU level are complicated; occasionally it takes a
long time until a regulation or directive becomes
enforced [23–25]. The EU pharmaceutical law consists
of diverse regulations and directives concerning nu-
merous pharmaceutical subjects like pharmacovigi-
lance, falsified medical products, drug marketing or
regulatory processes. Accessibility of acetylsalicylic acid
however is not regulated by European law but by na-
tional law [26]. Information about legal requirements
for pharmaceutical sales in EU countries was not found
in a systematic search in PubMed database. Therefore,
five countries of the EU were pre-selected. They were
chosen to investigate a cultural variety within the EU:
the UK, Ireland, Sweden, the Netherlands and Spain.
Governmental websites were used to gain information.
Due to different native languages on governmental web-
sites, no single search term could be used during the
search. Spain does only allow pharmacy sales of acetylsali-
cylic acid and was therefore excluded from the study.
Legislation in Sweden
The Swedish Medicines Act enables the Medical Prod-
uct Agency to control and monitor medical items in
Sweden. The agency is furthermore entitled to classify
drugs into prescription-free and prescription-only
medication [27, 28]. The maximum prescription-free
package size of acetylsalicylic acid consists of 500 mg
per unit with 20 tablets (tab) and 20 effervescent tablets
(TEF) per package and in a non-pharmacy store. In a
pharmacy, it is legal to purchase 50 tablets or 60 TEF
per package [29] (Table1).
Legislation in the United Kingdom
The Medicines and Healthcare Products Regulatory Agency
is an administrative body of the British Department of
Health; this agency is responsible for admission, monitor-
ing and safety of pharmaceuticals in the United Kingdom.
The Medicines Act from 1968 constitutes the legislation of
pharmaceuticals. Medicines are divided into three different
categories [30, 31]:
 Prescription-only medication
 Pharmacy sales medication
 General sales list medication (GSL)
Certain requirements in package size and strength
apply for acetylsalicylic acid in order to be listed as GSL
(Table 2). A maximum of 16 tablets of acetylsalicylic acid
325 mg may be offered in a non-pharmacy store [31].
Legislation in Ireland
The Irish Medicines Board forms the official agency of
the Department of Health and Children. This agency
regulates pharmaceutical matters like drug safety, drug
risks and monitoring. The Medical Product Regulations
Law regulates prescription and supply of pharmaceuti-
cals. Three categories for medication exist in Ireland.
Pharmaceuticals are either classified as:
 General sales medication
 Prescription-controlled medication from
schedule 1 (S1)
 Exemption from S1 medication.
These exemptions are either pharmaceuticals listed
in schedule 2 (S2) or S1 pharmaceuticals which are
labeled with maximum dose, maximum daily dose or
Table 1 Aspirin availability in Sweden, modified after [29, 37, 38]
Form Strength Pack size non-pharmacy Pack size pharmacy
Tab 250 mg 50 units 50 units
Tab 500 mg 20 units 50 units
TEF 500 mg 20 units 60 units
Table 2 Requirements for aspirin to listed GSL in the UK,
modified after [31]
Form Strength Pack size
TEF 500 mg 20 units
Powders or granules 650 mg 10 units
Tab or capsules 325 mg 16 units
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maximum treatment period. S2 medication can be of-
fered in non-pharmacies [32]. Acetylsalicylic acid is
classified as S2 medication and it is labeled with a
maximum daily dose of 4.0 g for patients aged more
than 12 years old. Subsequently, acetylsalicylic acid is
allowed to be sold prescription-free in pharmacies and
non-pharmacy stores [32, 33].
Legislation in the Netherlands
The Dutch medicine law came into effect in 2007 and was
enforced by the Ministry of National Health, Wellbeing
and Sports. This ministry instructs the administrative
body Medicines Evaluation Board to control pharmaceut-
ical safety and quality. Medications are divided into four
different categories in the Netherlands [34]:
 Prescription-only medication (UR)
 Pharmacy-only medication (UA)
 Pharmacy or drug store-only (UAD)
 Open sales medication (AV)
Acetylsalicylic acid does not belong to the AV list; it is
not permitted to sell acetylsalicylic acid outside of drug
stores or pharmacies. The medication holds UAD status
for a maximum pack size of 24 tablets of 500 mg; more
than 24 tablets per package may only be sold in pharma-
cies [35] (Table 3).
Conclusions
Acetylsalicylic acid is a drug which is not commonly
used in pediatrics. However, in case of accidental poison-
ing, it can lead to severe symptoms. Several countries in
the European Union are permitted to offer acetylsalicylic
acid prescription-free in pharmacies and non-pharmacy
stores without legal guidance on the storage position
within the store. Further investigation is needed to
analyze whether the pharmaceutical is placed in direct
accessibility to young children within these stores.
Abbreviations
AV, Open sale medication (algehele verkoop geneesmiddel); CNS, Central nervous
system; EC, European Commission; EP, European Parliament; GSL, General sales
list; S1, Schedule 1; S2, Schedule 2; Tab, tablets; TEF, Effervescent tablets; UA,
Pharmacy only medication (uitsluitend apotheek geneesmiddel); UAD, Pharmacy
or drug store only (uitsluitend apotheek of drogist geneesmiddel); UR, Prescription
only medication (uitsluitend recept geneesmiddel)
Acknowledgements
We thank G. Volante for expert help.
Authors’ contributions
MEM, CG, DB, DQ, and DAG have made substantial contributions to the
conception and design of the narrative review, acquisition of the review data
and have been involved in drafting and revising the manuscript. All authors
have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests. DAG was
member of the Committee for the Assessment of Intoxications of the
Federal Institute for Risk Assessment, Federal Republic of Germany.
Author details
1Institute of Occupational Medicine, Social Medicine and Environmental
Medicine, Departments of Female Health and Preventive Medicine, Goethe
University, Frankfurt am Main, Theodor-Stern-Kai 7, Frankfurt 60590, Germany.
2Department of Obstetrics and Gynecology, Keck School of Medicine,
University of Southern California, Los Angeles, CA, USA.
Received: 2 July 2015 Accepted: 25 May 2016
References
1. Mund ME et al. Paracetamol as a toxic substance for children: aspects of
legislation in selected countries. J Occup Med Toxicol. 2015;10:43.
2. Kliegman RM et al. Nelson Textbook of Pediatrics. 18th ed. Philadelphia:
Saunders Elsevier; 2007. Chapter 58.
3. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res.
2003;110(5-6):255–8.
4. Fertel BS, Nelson LS, Goldfarb DS. The underutilization of hemodialysis in
patients with salicylate poisoning. Kidney Int. 2009;75(12):1349–53.
5. Jacob J, Lavonas EJ. Falsely normal anion gap in severe salicylate poisoning
caused by laboratory interference. Ann Emerg Med. 2011;58(3):280–1.
6. Raza H, John A. Implications of altered glutathione metabolism in
aspirin-induced oxidative stress and mitochondrial dysfunction in HepG2
cells. PLoS One. 2012;7(4):e36325.
7. O'Malley GF. Emergency department management of the salicylate-poisoned
patient. Emerg Med Clin North Am. 2007;25(2):333–46. abstract viii.
8. Chyka PA et al. Salicylate poisoning: an evidence-based consensus guideline
for out-of-hospital management. Clin Toxicol (Phila). 2007;45(2):95–131.
9. Pena-Alonso YR et al. Aspirin intoxication in a child associated with
myocardial necrosis: is this a drug-related lesion? Pediatr Dev Pathol.
2003;6(4):342–7.
10. Michael JB, Sztajnkrycer MD. Deadly pediatric poisons: nine common agents
that kill at low doses. Emerg Med Clin North Am. 2004;22(4):1019–50.
11. Scherz RG. Prevention of childhood aspirin poisoning. Clinical trials with
three child-resistant containers. N Engl J Med. 1971;285(24):1361–2.
12. Centers for Disease Control and Prevention. Childhood Injury Report. 2008.
Accessed on 18.03.2015. Available from: http://www.cdc.gov/safechild/
images/CDC-childhoodinjury.pdf.
13. Australian Bureau of Statistics. Children's Injuries. 2015. Accessed on 18.3.
2015. Available from: http://www.abs.gov.au/ausstats/abs@.nsf/
Previousproducts/1301.0Feature%20Article152006?opendocument
&tabname=Summary&prodno=1301.0&issue=2006&num=&view=#.
14. Statistisches Bundesamt. Unfälle, Gewalt, Selbstverletzung bei Kindern und
Jugendlichen. 2011. Accessed on 18.3.2015. Available from: https://www.
destatis.de/DE/Publikationen/Thematisch/Gesundheit/Gesundheitszustand/
UnfaelleGewaltKinder5230001117004.pdf%3F__blob%3DpublicationFile.
15. Giftnotrufzentrale-Nord. Jahresbericht. 2012. Accessed on 24.02.2015.
Available from: http://www.giz-nord.de/cms/images/JaBe/2012/jabe12d.pdf.
16. World Health Organization. World directory of Poison Centers. 2015.
Accessed on 24.02.2015. Available from: http://www.who.int/gho/phe/
chemical_safety/poisons_centres/en/.
17. Poisons Information Centre of Ireland. Annual Report. 2014. Accessed on 17.03.
2016. Available from: http://www.poisons.ie/docs/Final%20Report%202014.pdf.
18. Swedish Poisons Information Centre. Annual Report. 2014. Accessed on 17.
03.2016. Available from: http://www.giftinformation.se/globalassets/
publikationer/arsrapport-2014_engelska.pdf.
19. Basavarajaiah S, Sigston P, Budack K. Severe salicylate poisoning treated
conservatively. J R Soc Med. 2004;97(12):587–8.
20. Minns AB, Cantrell FL, Clark RF. Death due to acute salicylate intoxication
despite dialysis. J Emerg Med. 2011;40(5):515–7.
Table 3 Aspirin availability in the Netherlands, modified after [35]
Form Strength Pack size Status
Tab 500 mg 24 tab UAD
Tab 500 mg > 24 tab UA
Mund et al. Journal of Occupational Medicine and Toxicology  (2016) 11:32 Page 4 of 5
21. Higgins RM, Connolly JO, Hendry BM. Alkalinization and hemodialysis in
severe salicylate poisoning: comparison of elimination techniques in the
same patient. Clin Nephrol. 1998;50(3):178–83.
22. Stolbach AI, Hoffman RS, Nelson LS. Mechanical ventilation was associated
with acidemia in a case series of salicylate-poisoned patients. Acad Emerg
Med. 2008;15(9):866–9.
23. Konsolidierte Fassung des Vertrags über die Europäische Union. 2008.
Accessed on 16.03.2015. Available from: http://eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri=OJ:C:2008:115:0013:0045:DE:PDF.
24. EU Info Deutschland. Gesetzgebung. Primäres und sekundäres
Gemeinschaftsrecht. 2015 [Accessed 18.03.2015]; Available from:
http://www.eu-info.de/europa/eu-richtlinien-verordnungen/.
25. Fretten C, Miller V. The European Union: a guide to terminology, procedures




26. The European Commission. DG Health and food safety. News and updates
on pharmaceuticals. 2015. Accessed on 18.05.2015. Available from: http://ec.
europa.eu/health/documents/eudralex/vol-1/index_en.htm#dir.
27. Medical Products Agency. Legislation within the Swedish Medical Products
Agency’s area of control. Accessed on 19.11.2014. Available from:
http://www.lakemedelsverket.se/english/overview/Legislation/.
28. Swedish Parliament. The Medicines Act. Accessed on 30.11.2014.
Available from: https://www.riksdagen.se/sv/Dokument-Lagar/Lagar/
Svenskforfattningssamling/Lakemedelslag-1992859_sfs-1992-859/.
29. Medical Products Agency. Detaljinformation Aspirin 500 mg tablett.
Accessed on 19.11.2014. Available from: http://www.lakemedelsverket.se/
LMF/Lakemedelsinformation/?nplid=19350131000010&type=product.
30. The National Archives. Medicines Act 1968. Accessed on 17.10.2014.
Available from: http://www.legislation.gov.uk/ukpga/1968/67/contents.
31. Medicines and Healthcare Products Regulatory Agency. Lists of substances.
2014. Accessed on 17.10.2014. Available from: http://www.mhra.gov.uk/
Howweregulate/Medicines/Licensingofmedicines/Legalstatusandre
classification/Listsofsubstances/.
32. Irish Statute Book. S.I. No. 540/2003 - Medicinal Products (Prescription and
Control of Supply) Regulations 2003. Accessed on 04.02.2015. Available
from: http://www.irishstatutebook.ie/2003/en/si/0540.html.
33. Weedle P, Clarke L. Pharmacy and Medicines Law in Ireland. 1 ed.
Pharmaceutical Press; 2011.
34. Inspectie voor de Gesondheidszorg. Ministerie voor Volksgesondheid,
Welzijn en Sport. London, UK: Geneesmiddelwet; 2014. Accessed on 18.10.2014.
Available from: http://wetten.overheid.nl/BWBR0021505/geldigheidsdatum_18-
10-2014#Hoofdstuk5.
35. College ter Beoordeling van Geneesmiddelen. Indelingsoverzicht NSAID.
2009. Accessed on 17.10.2014. Available from: http://www.cbg-meb.nl/NR/
rdonlyres/4082C75F-9EF2-4DC8-B513-8FD7DB2DCACA/0/Indelingsoverzicht
NSAID.pdf
36. Kleemann A et al. Pharmaceutical substances. 4th ed. Stuttgart: Georg
Thieme Verlag; 2001.
37. Medical Products Agency. Receptfria läkemedel tillåtna för försäljning på andra
försäljningsställen än apotek. 2014. Accessed on 19.11.14. Available from:
http://www.lakemedelsverket.se/upload/apotek-och-handel/OTC%20listor/gk_
otc%20detaljhandel%20enl%20lvfs%202009_2014-10-02.pdf.
38. Medical Products Agency. Detaljinformation Albyl minor 250 mg tablet.
Accessed on 19.11.2014. Available from: http://www.lakemedelsverket.se/
LMF/Lakemedelsinformation/?nplid=19550809000018&type=product.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Mund et al. Journal of Occupational Medicine and Toxicology  (2016) 11:32 Page 5 of 5
